Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinyouli for Neutropenia in Hemophagocytic Syndrome
NCT04500886Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Randomised, open-label trial of pegylated granulocyte colony-stimulating factor in neutropenia (2 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Duration of grade IV neutropenia up to 1 year. Status: unknown.
02
Drugs
pegylated granulocyte colony-stimulating factor
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04500886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500886.